logo
Building Trust in Healthcare AI: India's Path from Potential to Practice

Building Trust in Healthcare AI: India's Path from Potential to Practice

Time of India2 days ago
New Delhi: As India's healthcare sector grapples with rising patient volumes, workforce shortages and systemic capacity constraints, Artificial Intelligence (AI) is increasingly emerging as a practical and powerful tool to bridge critical gaps.
Recent discussions among healthcare leaders and policymakers have spotlighted how AI is no longer just a futuristic concept but a present-day ally for clinicians navigating complex healthcare realities.
The recently unveiled Future Health Index (FHI) 2025 India report was marked by an engaging discussion with some of India's leading healthcare experts and advocates. The event underscored how India is now poised to transition from viewing AI as a tool of potential to embracing it as a practical solution in real world healthcare settings.
With a special address by H.E. Ms. Marisa Gerards, Ambassador of the Kingdom of the Netherlands to India, Nepal, and Bhutan, the event featured a thought-provoking panel discussion with leading healthcare experts including Mr. Neeraj Jain, Director - Growth Operations, Asia, Middle East and Europe (AMEE), PATH; Dr. Ratna Devi, Board Member at IAPO and CEO of DakshamA Health and Mr. Bharath Sesha, Managing Director, Philips Indian Subcontinent. The session was moderated by Ms. Prathiba Raju, Senior Assistant Editor at ETHealthWorld, The Economic Times Group.
According to the India-specific findings in the FHI report, 76% of healthcare professionals believe AI will help improve patient outcomes, while over 80% feel AI can save lives by enabling timely care. These figures point to a growing confidence among India's clinical community in the technology's ability to enhance not replace human decision-making.
'India stands at a pivotal moment in its healthcare transformation,' said Bharath Sesha, Managing Director, Philips Indian Subcontinent. 'There is growing confidence in AI, not just as a tool for efficiency, but as a catalyst for improved outcomes, broader access, and more empowered healthcare professionals.
The
Future Health Index 2025
findings reaffirm what we've long believed: when applied with purpose, technology can bridge the gap between capability and capacity.
Trust in both the technology and the intent behind it is essential to scaling AI in a meaningful way. Cross-sector collaboration is equally critical. By bringing together clinicians, technologists, policymakers, and patients, we can co-create solutions that are clinically relevant, ethically sound, and scalable across India's diverse healthcare ecosystem.'
Global best practices suggest that collaboration is key. The development and deployment of
AI in healthcare
must involve a broad set of stakeholders. This inclusive approach is especially vital in countries like India, where the scale and diversity of the health system present both opportunities and risks.
'
Healthcare innovation
must be people-centric and globally responsible,' said H.E. Ms. Marisa Gerards, Ambassador of the Kingdom of the Netherlands to India, Nepal and Bhutan. 'During the launch of the 10th edition of Future Health Index 2025 report commissioned by Philips, we had a meaningful discussion with the Indian stakeholders thinking not just about what technology can do, but how it can be applied ethically, equitably, and effectively.'
The findings from the report also reveal a broadening acceptance of AI in everyday practice. 72 per cent of professionals say it supports accurate, real-time clinical decision-making, while 75 per cent believe it is particularly valuable for training junior staff and expanding access in underserved areas.
'AI is no longer a choice it's the only viable path to delivering care at scale for a nation of 1.5 billion people,' noted Mr. Neeraj Jain, Director - Growth Operations, Asia, Middle East and Europe (AMEE), PATH. 'But for it to work, our entire ecosystem must be prepared to adopt it responsibly. That means accelerating adoption while ensuring AI tools are developed in close consultation with clinicians, so they are fit for purpose and trusted at the point of care.'
While trust in AI is growing, it remains conditional. 67 per cent of healthcare professionals voiced concern over data bias, highlighting the risk of inequities if AI systems are not trained on representative datasets. Questions around legal liability (44%) and defined guardrails for clinical use (45%) also persist.
'
Building trust in AI
is critical,' said Dr. Ratna Devi, Board Member at IAPO and CEO of DakshamA Health. 'People need clarity on how these tools work and assurance that they are safe and reliable. The doctor–patient ratio in India is unlikely to change dramatically, so AI must be seen as a tool to augment, not replace doctors. It can enhance care delivery, improve efficiency, and help drive change, but it must always complement the human touch.'
The FHI 2025 findings also highlight the importance of sustained investment in education and digital capacity-building. Empowering healthcare workers to understand and trust AI, will be essential to mainstream adoption and to ensuring long-term success.
As AI moves further into the clinical mainstream, India finds itself at a pivotal moment. With rising readiness among professionals, deepening digital infrastructure, and increasing cross-sectoral momentum - the time to build trust and act is now.
Download the full FHI 2025 India Report here
Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine
Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine

Time of India

time7 hours ago

  • Time of India

Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine

When Routine Surgery Unveiled a Rare Mystery A Blood Sample's Journey India's Rising Role in Rare Blood Research Why CRIB Changes the Game In a remarkable turn of events that is being hailed as a historic medical milestone, a 38-year-old woman from Karnataka has become the first person in the world to be identified with a previously unknown blood group antigen — officially named CRIB. According to a report from Times of India, the discovery, unveiled at the 35th Regional Congress of the International Society of Blood Transfusion (ISBT) in Milan in June 2025, is now being seen as a potential game-changer in the fields of transfusion medicine and organ transplant name CRIB isn't random — it stands for Cromer-India-Bangalore , paying homage to the antigen's family system and the city where this scientific breakthrough took medical mystery began in an unsuspecting operation theatre. Admitted for cardiac surgery in Kolar district, the patient, believed to have the widely common O Rh+ blood group, was expected to receive a standard transfusion. But in a shocking twist, her blood reacted adversely to all compatible O-positive donor should have been a routine procedure soon spiraled into a global medical investigation. With every available unit failing the compatibility test, the hospital escalated the case to the Advanced Immunohematology Reference Laboratory at Rotary Bangalore TTK Blood Centre.'We found her blood was panreactive — it reacted with every single donor sample,' said Dr. Ankit Mathur of the Rotary Centre. 'Even 20 of her closest family members didn't match. That's when we knew this was something the world hadn't seen before.'With local testing hitting a wall, blood samples were sent overseas to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK. Ten months of meticulous molecular and serological testing later, researchers identified an entirely new antigen under the Cromer (CR) blood group discovery was not just a scientific revelation — it was a collaborative triumph. The CRIB antigen now enters medical history as a reference point for future studies and emergency care cases around the the life-threatening stakes, doctors managed to perform the cardiac surgery without requiring a transfusion — a risky but ultimately successful decision. The woman not only survived but ended up redefining how the world views 'universal' blood isn't the first time India has made headlines in rare blood discoveries. Dr. Mathur notes that India has previously identified and reported cases involving Rh null and In b negative types, which were presented at international platforms. However, CRIB's identification may prove even more significant due to its global further address the rising need for rare donor matches, the Rotary Bangalore TTK Blood Centre, in collaboration with Karnataka State Blood Transfusion Council, ICMR's IIH in Mumbai, and ISBT, has launched a Rare Donor Registry Rare blood groups like CRIB are often difficult to detect and nearly impossible to match in emergencies. By adding a new antigen to global databases, CRIB opens the door to improved transfusion safety protocols, enhanced compatibility testing, and better organ transplant success rates."This is not just a scientific win — it's a humanitarian one," said a representative from ISBT. 'CRIB will help protect lives where standard blood group typing fails.'

Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine
Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine

Economic Times

time8 hours ago

  • Economic Times

Bengaluru lab fails to match woman's blood type to anyone, discovers first human with ultra-rare antigen that could revolutionize medicine

iStock In a groundbreaking discovery, a woman from Karnataka has been identified with a novel blood group antigen, CRIB, unveiled at the ISBT congress in Milan. This finding, a potential game-changer for transfusion medicine and organ transplant safety, emerged after her blood reacted adversely to all compatible donor units during cardiac surgery. (Image: iStock) In a remarkable turn of events that is being hailed as a historic medical milestone, a 38-year-old woman from Karnataka has become the first person in the world to be identified with a previously unknown blood group antigen — officially named CRIB. According to a report from Times of India, the discovery, unveiled at the 35th Regional Congress of the International Society of Blood Transfusion (ISBT) in Milan in June 2025, is now being seen as a potential game-changer in the fields of transfusion medicine and organ transplant safety. The name CRIB isn't random — it stands for Cromer-India-Bangalore, paying homage to the antigen's family system and the city where this scientific breakthrough took place. The medical mystery began in an unsuspecting operation theatre. Admitted for cardiac surgery in Kolar district, the patient, believed to have the widely common O Rh+ blood group, was expected to receive a standard transfusion. But in a shocking twist, her blood reacted adversely to all compatible O-positive donor units. What should have been a routine procedure soon spiraled into a global medical investigation. With every available unit failing the compatibility test, the hospital escalated the case to the Advanced Immunohematology Reference Laboratory at Rotary Bangalore TTK Blood Centre. 'We found her blood was panreactive — it reacted with every single donor sample,' said Dr. Ankit Mathur of the Rotary Centre. 'Even 20 of her closest family members didn't match. That's when we knew this was something the world hadn't seen before.' With local testing hitting a wall, blood samples were sent overseas to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK. Ten months of meticulous molecular and serological testing later, researchers identified an entirely new antigen under the Cromer (CR) blood group system. The discovery was not just a scientific revelation — it was a collaborative triumph. The CRIB antigen now enters medical history as a reference point for future studies and emergency care cases around the globe. Despite the life-threatening stakes, doctors managed to perform the cardiac surgery without requiring a transfusion — a risky but ultimately successful decision. The woman not only survived but ended up redefining how the world views 'universal' blood types. This isn't the first time India has made headlines in rare blood discoveries. Dr. Mathur notes that India has previously identified and reported cases involving Rh null and In b negative types, which were presented at international platforms. However, CRIB's identification may prove even more significant due to its global implications. To further address the rising need for rare donor matches, the Rotary Bangalore TTK Blood Centre, in collaboration with Karnataka State Blood Transfusion Council, ICMR's IIH in Mumbai, and ISBT, has launched a Rare Donor Registry. Rare blood groups like CRIB are often difficult to detect and nearly impossible to match in emergencies. By adding a new antigen to global databases, CRIB opens the door to improved transfusion safety protocols, enhanced compatibility testing, and better organ transplant success rates. "This is not just a scientific win — it's a humanitarian one," said a representative from ISBT. 'CRIB will help protect lives where standard blood group typing fails.' v

Virtual labs with AI scientists produce promising result in Stanford study
Virtual labs with AI scientists produce promising result in Stanford study

Time of India

time18 hours ago

  • Time of India

Virtual labs with AI scientists produce promising result in Stanford study

Virtual scientists in a virtual lab at Stanford University are coming up with unorthodox ways to address clinical challenges, researchers reported on Tuesday in Nature. The virtual lab is modeled after a well-established Stanford School of Medicine research group, complete with a principal investigator and seasoned scientists, the report says. As in human-run research labs, the virtual lab has regular meetings during which agents generate ideas and engage in a conversational back-and-forth. They also have one-on-one meetings, allowing the virtual lab members to meet with the virtual principal investigator individually to discuss ideas. Unlike human meetings, the virtual gatherings take a few seconds or minutes. When humans tasked the virtual team with devising a better vaccine for the SARS-CoV-2 virus that causes COVID-19, they equipped the virtual scientists with tools and software to stimulate creative "thinking" skills. The virtual scientists even created their own wish list. "They would ask for access to certain tools, and we'd build it into the model to let them use it," study leader James Zou said in a statement. Instead of opting for the usual vaccine design using an antibody, the AI team came up with using a nanobody, an antibody fragment that's smaller and simpler. "From the beginning of their meetings, the AI scientists decided that nanobodies would be a more promising strategy," Zou said. "They said nanobodies are typically much smaller than antibodies, so that makes the machine learning scientist's job much easier," Zou said, "because when you computationally model proteins, working with smaller molecules means you can have more confidence in modeling and designing them." When humans created the AI researchers' nanobody in a real-world lab, they found it was stable and could attach itself to one of the COVID virus variants more tightly than existing antibodies - a key factor in determining vaccine effectiveness. Aside from the initial prompt, the main guideline consistently given to the AI lab members was budget-related. Zou estimates that he or his lab members intervene about 1% of the time. "I don't want to tell the AI scientists exactly how they should do their work. That really limits their creativity," Zou said. "I want them to come up with new solutions and ideas that are beyond what I would think about." SCIENTISTS FIND GENES THAT CAUSE STUTTERING A new study found a clear genetic basis for stuttering, the speech disorder that affects more than 400 million people worldwide. Overall, as reported in Nature Genetics, the researchers identified 57 distinct regions on 48 genes associated with stuttering. Some of the same genetic variants involved in stuttering can also contribute to autism, depression and musicality, they found. Stuttering, characterized by syllable and word repetitions, sound prolongations, and breaks between words, is the most common fluency disorder, the researchers said. "There have been hundreds of years of misconceptions about what causes stuttering, from ideas about left-handedness to childhood trauma to overbearing mothers," study leader Jennifer (Piper) Below of Vanderbilt University Medical Center in Nashville said in a statement. "Rather than being caused by personal or familial failings or intelligence, our study shows that stuttering is influenced by our genes." Young people who stutter report increased bullying, decreased classroom participation, and a more negative educational experience, her team noted. Stuttering can also negatively impact employment opportunities and perceived job performance, as well as mental and social well-being. Dillon Pruett, a postdoctoral fellow at Vanderbilt and a co-author of the study, stutters. "As someone personally affected, I wanted to contribute to this body of research," he said. "Our study found that there are many genes that ultimately contribute to stuttering risk, and we hope to use this knowledge to dispel stigma related to stuttering and also to hopefully develop new therapeutic approaches in the future." AT THE SIGHT OF A SICK PERSON, THE BRAIN GOES ON ALERT At the mere sight of a possibly contagious person, the human brain launches its germ-fighting preparations, researchers say. In virtual reality experiments using Google's Oculus Rift headsets, 248 healthy young adults were approached by human-like avatars, some of which showed visible signs of infection, such as rashes or coughing. Other avatars appeared neutral or fearful. As the infectious avatars moved closer, noninvasive monitoring showed changes in brain regions involved in integrating awareness of the body's position, movement, and relationship to the surrounding environment, which was not seen in response to the approaching neutral or fearful faces, the researchers reported in Nature Neuroscience. Participants were more reactive to touch when the sick-looking avatars were nearby, the researchers also found. Blood samples showed that exposure to the infectious-appearing avatars triggered an increase in volunteers' innate lymphoid cell activity, a key component of the immune system, which is typically seen during responses to real infections or vaccines. The results illustrate the power of the brain "to predict what is going on (and) to select the proper response," study co-author Andrea Serino of University Hospital of Lausanne, Switzerland said in an accompanying news article in the journal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store